Please login to the form below

Not currently logged in
Email:
Password:

Entyvio

This page shows the latest Entyvio news and features for those working in and with pharma, biotech and healthcare.

Takeda’s Entyvio tops Humira in ulcerative colitis

Takeda’s Entyvio tops Humira in ulcerative colitis

After a year, 31.3% of patients treated with intravenous Entyvio, given every two months after a lead-in period, were in remission from the inflammatory bowel disease. ... Entyvio is an important growth product for Takeda as it is bearing the brunt of

Latest news

More from news
Approximately 6 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Forging a path in specialty care Forging a path in specialty care

    Adcetris (for Hodgkin Lymphoma), Entyvio (for ulcerative colitis and Crohn's Disease) and future compound Ninlaro (an oral protease inhibitor for relapsed/refractory multiple myeloma) which was approved by the FDA ... The best example is Entyvio. It

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics